ArticleBiomarkers in medicine2025
Systemic immune-inflammation index as a biomarker for stroke prognosis: insights from a multi-time point analysis.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate dehydrogenase and short-term mortality in ICU patients with ischemic stroke: a single-center retrospective analysis of MIMIC-IV.European journal of medical research · 2025Article
- PAI-1, MMP-9, and NLR combined with NIHSS for predicting 90-day poor functional outcome in elderly acute ischemic stroke: a prospective observational cohort study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to investigate the association between the systemic immune-inflammation index (SII) and prognosis trajectories in ischemic stroke(IS).
methodsPatients from two tertiary hospitals in Suzhou were included in this study. SII was calculated as neutrophils×platelets/lymphocytes, and patients were categorized into quartiles based on SII values. Latent class growth modeling (LCGM) was employed to describe the trajectories of modified Rankin Scale (mRS) at different time points.Logistic regression models were used to evaluate the association between SII quartiles and prognosis trajectories at multiple time points (14 days, 1 month, 3 months, 6 months)and prognostic trajectories.
resultsPatients in the highest quartile (Q4) of SII had a significantly higher risk of adverse outcomes compared to those in the lowest quartile (Q1). A three-group model was identified as the optimal trajectory model for stroke prognosis. SII was associated with 4.06-fold increased odds (95% CI: 1.64-10.08) of unfavorable prognosis trajectories. Per standard deviation increase in the logarithmic SII, the odds of unfavorable prognosis trajectories were 1.64 (95% CI: 1.18-2.29).
conclusionsBaseline SII is significantly associated with unfavorable outcome trajectories across multiple time points in IS. These findings highlight the potential value of SII as a predictive biomarker for sequential prognosis in stroke patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.